This partnership
is personal

Accurate solutions aimed at altering the face and future of cancer

Genomics in Drug Development

Next-generation sequencing (NGS) enables researchers and drug developers to better understand the biology that drives cancer predisposition and proliferation. These insights have led to the development of targeted therapeutics and multi-analyte tumor analysis. This, in turn, has opened the door for novel methods to monitor cancer treatment and recurrence.

llumina brings innovation to oncology drug development by offering comprehensive genomic solutions and working in collaboration with leading pharmaceutical providers.

Companion Diagnostics Development

As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.

Learn More
NGS for Drug Development

NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.

Learn More
Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
Image
A Leading Vision

Watch Dr. Richard Klausner, CMO at Illumina, describe the company’s initiatives to transform the future of oncology with genomics.

View Video
Image
Precision Oncology Partnering

Learn more about our pharmaceutical partnership strategy for development of oncology diagnostics.

Access PDF
Image
Celebrate the Genome

Reflect what the power of the genome means for drug development and share it. Educate others. Promote the promise of the genome.

Learn More